BioSynthetics

Executive Summary

BioSynthetics is a Swiss synthetic biology company developing novel biologic drugs and enzymes for therapeutic and industrial applications, with a primary focus on inborn errors of metabolism. Founded in 2019 and headquartered in Zurich, the company has raised $260 million to engineer complex protein structures and biosynthetic pathways. Its platform leverages advanced metabolic engineering to produce therapies that address genetic metabolic disorders, an area with high unmet need and limited treatment options. By designing enzyme replacement therapies and targeted biologics, BioSynthetics aims to correct underlying metabolic deficiencies and improve patient outcomes. Currently in Phase 1 clinical development, BioSynthetics is advancing its lead candidates through early-stage trials. The substantial funding and specialized focus position it well within the competitive synthetic biology landscape. Upcoming catalysts include initial efficacy data from its lead program, potential partnerships for industrial enzyme applications, and progress toward a Series B funding round. While early-stage risk remains, the company's strong capital position and clear therapeutic focus provide a solid foundation for near-term value creation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 efficacy data for lead metabolic therapy40% success
• Q4 2026Strategic partnership for industrial enzyme platform55% success
• Q1 2027Series B financing round70% success